SEC Info - Polewaczyk James F - ‘3’ for 1/15/20 re: Idexx Laboratories Inc./DE

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

POLEWACZYK JAMES F

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

04092

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
1/15/20

3. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Executive Vice President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	15,899	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Unit	⁽¹⁾	⁽¹⁾	Common Stock	2,281 ⁽¹⁾	⁽¹⁾	D
Non-Qualified Stock Option (right-to-buy)	⁽²⁾	2/13/24	Common Stock	1,126 ⁽¹⁴⁾	62 ⁽¹⁴⁾	D
Non-Qualified Stock Option (right-to-buy)	⁽³⁾	5/31/14	Common Stock	4,028 ⁽¹⁴⁾	62.24 ⁽¹⁴⁾	D
Incentive Stock Option (right-to-buy)	⁽⁴⁾	2/13/25	Common Stock	1,256 ⁽¹⁴⁾	79.54 ⁽¹⁴⁾	D
Non-Qualified Stock Option (right-to-buy)	⁽⁵⁾	2/13/25	Common Stock	11,110 ⁽¹⁴⁾	79.54 ⁽¹⁴⁾	D
Non-Qualified Stock Option (right-to-buy)	⁽⁶⁾	2/13/26	Common Stock	12,627	67.85	D
Incentive Stock Option (right-to-buy)	⁽⁷⁾	2/13/25	Common Stock	1,476	67.85	D
Non-Qualified Stock Option (right-to-buy)	⁽⁸⁾	2/13/27	Common Stock	7,151	141.6	D
Incentive Stock Option (right-to-buy)	⁽⁹⁾	2/13/27	Common Stock	706	141.6	D
Non-Qualified Stock Option (right-to-buy)	⁽¹⁰⁾	2/13/28	Common Stock	5,865	178.26	D
Incentive Stock Option (right-to-buy)	⁽¹¹⁾	2/13/28	Common Stock	560	178.26	D
Non-Qualified Stock Option (right-to-buy)	⁽¹²⁾	2/13/29	Common Stock	5,711	206.94	D
Incentive Stock Option (right-to-buy)	⁽¹³⁾	2/13/29	Common Stock	483	206.94	D

Explanation of Responses:

(1) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").

(2) Grant of option to buy 6,039 shares of Issuer common stock that vest in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split.

(3) Grant of option to buy 10,071 shares of Issuer common stock that vest in five annual installments beginning on June 1, 2015, without giving effect to the Stock Split.

(4) Grant of option to buy 628 shares of Issuer common stock that vests in one installment on February 14, 2020, without giving effect to the Stock Split.

(5) Grant of option to buy 5,555 shares of Issuer common stock that vest in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split.

(6) Grant of option to buy 12,627 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2017.

(7) Grant of option to buy 1,476 shares of Issuer common stock that vests as to 1 share on February 14, 2018, 1 share on February 14, 2019, and as to the remainder on February 14, 2021.

(8) Grant of option to buy 7,151 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2018.

(9) Grant of option to buy 706 shares of Issuer common stock that vests in one installment on February 14, 2022.

(10) Grant of option to buy 5,865 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2019.

(11) Grant of option to buy 560 shares of Issuer common stock that vests in one installment on February 14, 2023.

(12) Grant of option to buy 5,711 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2020.

(13) Grant of option to buy 483 shares of Issuer common stock that vests in one installment on February 14, 2024.

(14) The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

	/s/ Lily J. Lu, Attorney-in-Fact for James F. Polewaczyk	1/24/20
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Polewaczyk James F – ‘3’ for 1/15/20 re: Idexx Laboratories Inc./DE

On: Friday, 1/24/20, at 5:02pm ET · For: 1/15/20 · Accession #: 1567619-20-1519 · File #: 0-19271

Previous ‘3’: ‘3’ on 2/7/07 for 2/5/07 · Latest ‘3’: This Filing

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents

‘3’ — Initial Statement of Beneficial Ownership of Securities by an Insider — doc1.xml/2.6